South Korea’s Fair Trade Commission has claimed that Qualcomm blocked Samsung from selling its own Exynos processors to other manufacturers through a patent licensing deal, ZDNet reports.
The deal reportedly dates back to 1993, when an agreement was reached to allow Samsung to make its own modem chips using certain CDMA patents, but only for use in its own phones. Subsequently, either Samsung or the phone maker would’ve had to pay Qualcomm licensing fees if they wanted to use an Exynos SoC in a non-Samsung phone. Talks between the two to reach an alternative agreement reportedly broke down in 2013.
Since then, non-Samsung Exynos phones have been few and far between, with the Meizu Pro 5, being a rare example.
Qualcomm’s patents are considered standards essential patents, which must be licensed under fair terms, and the chip giant fell foul of Korea’s regulators last December, when it was handed an $865 million fine. Qualcomm is currently fighting a ruling which would require it to change its licensing terms.
Full Content: ZD Net
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan